UK Backs All 44 Recommendations for NHS AI Regulation

The UK government will accept every one of the 44 recommendations from the National Commission into the Regulation of AI in Healthcare, the Department of Health and Social Care said on 6 October 2026 — turning a doctor-led advisory panel’s blueprint, published less than a month earlier, into stated government policy. Alongside the response, the Medicines and Healthcare products Regulatory Agency opened applications for the third phase of its AI Airlock regulatory sandbox, with testing themes the agency says are drawn directly from the Commission’s report.

From proposal to policy, in under a month

MHRA formed the National Commission in September 2025 specifically to advise on a future regulatory framework for AI in healthcare, bringing together clinicians, AI researchers, and regulators under independent leadership rather than writing the framework itself. That design was meant to give the eventual recommendations standing: a panel led by practising NHS doctors, not the regulator marking its own homework. The Commission’s report, delivered 10 September 2026, argued that the UK’s current approach — built around a one-time pre-market check — does not fit software that keeps learning and changing after it ships. The government’s 6 October response accepts that argument in full, rather than picking selectively among the 44 recommendations, which is the detail regulatory teams should note: this is not a partial or qualified endorsement.

What “lifecycle-based” regulation commits the government to

The Commission's central conclusion was that AI-enabled medical devices should be assessed and monitored throughout their working life, not cleared once and left alone. That implies two things sponsors have not had to plan for under the current UK MDR regime: a system for providers to report how a tool performs in live clinical use, including malfunctions or signs it is degrading patient care, and some mechanism for staged or conditional authorisation that lets a model earn broader clearance as real-world evidence accumulates. The government's response commits to building that delivery plan but does not itself amend the Medical Devices Regulations 2002 or create new statutory reporting duties — those steps, if they follow, will arrive separately through guidance or legislation.

The AI Airlock becomes the near-term entry point

For sponsors who want to engage before the framework is fully built out, the AI Airlock is the concrete step available now. The sandbox lets manufacturers trial AIaMD products with MHRA and NHS partners under controlled conditions, feeding findings back into policy; Phase 2's cohort worked through predetermined change control plans, how scope of intended use should be drawn for adaptive models, and the particular problems of AI-powered IVDs. MHRA has said Phase 3's call for applications, opened 6 October, will test themes informed directly by the Commission's recommendations — the clearest signal yet of how lifecycle regulation might work in practice before it is written into any binding standard.

• What changed: a government policy commitment to accept all 44 Commission recommendations and pursue lifecycle-based AI regulation — not yet a change to the Medical Devices Regulations 2002.
• What opened: MHRA's call for applications to AI Airlock Phase 3, themed around the Commission's recommendations and building on Phase 2's change-control and post-market surveillance work.
• What to watch: how MHRA operationalises continuous post-market monitoring and provider performance reporting — the mechanics that will determine what UK AIaMD sponsors must actually do differently.
• The pattern: this is the government's second full acceptance of an AI-health advisory body's recommendations in eighteen months, after the Regulatory Horizons Council's 15 recommendations in March 2025.

Frequently asked questions

What did the UK government announce on 6 October 2026?

The Department of Health and Social Care published its formal response to the National Commission into the Regulation of AI in Healthcare, accepting all 44 of the Commission's recommendations and setting out a UK-wide delivery plan built around lifecycle-based regulation of AI-enabled health technologies.

What is the National Commission into the Regulation of AI in Healthcare?

An independent advisory body MHRA launched on 26 September 2025, co-chaired by Prof. Alastair Denniston (University of Birmingham and University Hospitals Birmingham NHS Foundation Trust) and Prof. Henrietta Hughes OBE (Patient Safety Commissioner for England). Its 119-page final report, published 10 September 2026, set out 44 recommendations organised around three principles: proportionate lifecycle regulation, system-wide responsibility, and trust, transparency and predictability.

What changed with the AI Airlock the same day?

MHRA opened the call for applications for Phase 3 of the AI Airlock, its regulatory sandbox for AI as a medical device (AIaMD). The agency says Phase 3's testing themes are drawn directly from the Commission's recommendations, building on Phase 2's work on predetermined change control plans, post-market surveillance, scope of intended use, and AI-powered in vitro diagnostics.

Does acceptance of the recommendations change the law immediately?

No. The government's response is a policy commitment to a delivery plan, not a change to the UK Medical Devices Regulations. Lifecycle-based obligations — such as continuous post-market performance monitoring and incident reporting — will need to be implemented through further guidance, legislation, or MHRA programmes such as the AI Airlock before they bind sponsors.